Rephonic
Artwork for Kidney Compass: Navigating Clinical Trials

Kidney Compass: Navigating Clinical Trials

Kidney Compass: Navigating Clinical Trials
Iga Nephropathy
Chronic Kidney Disease
SGLT2 Inhibitors
Proteinuria
Sibeprenlimab
Empagliflozin
Finerenone
Albuminuria
Nudge-Ckd
Smart-C
Iron Deficiency In Kidney Disease
Telitassusept
Obinutuzumab
Alport Syndrome
Sparsentan
Digital Infrastructure
Atacicept
Origin 3
Atherosclerotic Cardiovascular Disease
Lupus Nephritis

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease.

PublishesDailyEpisodes20Foundeda year ago
Number of ListenersCategories
Health & FitnessMedicine

Listen to this Podcast

Artwork for Kidney Compass: Navigating Clinical Trials

Latest Episodes

At the World Congress of Nephrology 2026 in Yokohama, Japan, growing attention is being paid not just to whether therapies improve outcomes in chronic kidney disease, but how they work at a mechanistic level.

In this episode of Kidney Compass, host... more

Iron deficiency is increasingly recognized as a clinically meaningful yet underexplored contributor to morbidity in kidney disease, extending beyond its traditional association with anemia. In populations such as kidney transplant recipients, where g... more

The treatment landscape for IgA nephropathy (IgAN) continues to evolve at a rapid pace, and new data presented at the World Congress of Nephrology (WCN) in Yokohama, Japan, suggest a potential shift in how clinicians approach disease modification in ... more

As the treatment landscape for IgA nephropathy grows increasingly complex, new data presented at the World Congress of Nephrology 2026 in Yokohama, Japan, are beginning to clarify how emerging therapies may work together.

In this episode of Kidney C... more

New phase 3 data released by Vor Bio underscore the potential of telitacicept, a dual BLyS/APRIL inhibitor, as a disease-modifying therapy for IgA nephropathy (IgAN), particularly for patients at high risk of progression.

In this special edition e... more

Welcome to Kidney Compass: Navigating Clinical Trials!

In this special edition episode of Kidney Compass: Navigating Clinical Trials, host Brendon Neuen, MBBS, PhD, is joined by Sophia Zoungas, MBBS, PhD, an endocrinologist and head of the School ... more

In this special edition episode of Kidney Compass: Navigating Clinical Trials, host Brendon Neuen, MBBS, PhD sits down with Daniel Gale, PhD, MB BChir, is the director of the UK-based RaDaR Registry and the St Peter's Chair of Nephrology at Universit... more

In this special edition episode of Kidney Compass: Navigating Clinical Trials, host Shikha Wadhwani, MD, MS, sits down with Brad Rovin, MD, Lee A. Hebert Distinguished Professor of Nephrology at The Ohio State University Wexner Medical Center, to dis... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Recent Guests

David Cherney
Leader in diabetes complications research
University of Toronto (informal affiliation in conversation)
Episode: REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD
Martin de Borst
Professor, UMCG Groningen, Netherlands
UMCG Groningen
Episode: IV Iron and Functional Outcomes in Kidney Transplant Recipients
Hong Zhang
Professor from Peking University First Hospital, IGF nephropathy researcher
Peking University First Hospital
Episode: Phase 3 Data on Telitacicept in IgA Nephropathy at ASN Kidney Week 2025
Jicheng Liu
Professor from China, IGF nephropathy researcher
Unspecified Chinese institution
Episode: Phase 3 Data on Telitacicept in IgA Nephropathy at ASN Kidney Week 2025
Sophia Zoungas
Professor of Medicine at Monash University
Monash University
Episode: Understanding Renal Outcomes in SURPASS-CVOT, With Sophia Zoungas, MBBS, PhD
Danny Gale
St. Peter's Chair of Nephrology at University College London; Director of the RaDaR Registry
University College London, RaDaR Registry
Episode: Setanaxib, Alport Syndrome, and RaDaR Updates at Kidney Week 2025, With Danny Gale, MB BChir, PhD
Brad Rovin
Division chief of nephrology and lupus nephritis expert
The Ohio State University Wexner Medical Center
Episode: Obinutuzumab, REGENCY, & Updates in Lupus Nephritis, With Brad Rovin, MD
Richard Lafayette, MD
Professor of Medicine at Stanford University
Stanford University
Episode: Kidney Compass: Atacicept and ORIGIN 3 at Kidney Week 2025, with Richard Lafayette, MD
Tor Biering-Sørensen
Professor from the University of Copenhagen
University of Copenhagen
Episode: NUDGE-CKD and the Power of Pragmatic Trials

Hosts

Brendon Neuen
Host of Kidney Compass: Navigating Clinical Trials; nephrology clinician and researcher
Shikha Wadhwani
Co-host of Kidney Compass: Navigating Clinical Trials; nephrology clinician and researcher

Reviews

5.0 out of 5 stars from 21 ratings
  • Insightful podcast

    Thank you for this amazing podcast. It’s been really helpful to keep up with upcoming treatments for iga nephropathy patients

    Apple Podcasts
    5
    abcdefghijoe
    Australia9 months ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Strong emphasis on translating research into patient care; engaging host-guest discussions.
Insightful, practical take on trial data for IgA nephropathy and CKD.
High-quality guests with deep trial knowledge.
Great for keeping up with evolving nephrology trials and real-world implications.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Top Medicine Podcasts

Health Report
Health ReportABC Australia
What's That Rash?
What's That Rash?ABC Australia
FoundMyFitness
FoundMyFitnessRhonda Patrick, Ph.D.
unPAUSED with Dr. Mary Claire Haver
unPAUSED with Dr. Mary Claire HaverAudacy | Mary Claire Haver, MD
The Dr. Hyman Show
The Dr. Hyman ShowDr. Mark Hyman
The Dr Vonda Show
The Dr Vonda ShowDr. Vonda Wright
The Peter Attia Drive
The Peter Attia DrivePeter Attia, MD
The Dr. Gabrielle Lyon Show
The Dr. Gabrielle Lyon ShowDr. Gabrielle Lyon

Talking Points

Recent interactions between the hosts and their guests.

NUDGE-CKD and the Power of Pragmatic Trials
Q: What was the design and rationale of the Nudge-Ckd trial in Denmark?
It was a nationwide randomized, two-by-two editorial implementation trial that nudged both patients and general practitioners with simple letters to increase uptake of guideline-directed therapies for CKD; it leveraged Danish registries and e-book notifications to identify and contact participants.
REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD
Q: What are the implications of Remodel for non-diabetic kidney disease and the broader CKD population?
The mechanistic observations—endothelial and inflammatory pathway modulation and intra-renal fat reduction—could be relevant to non-diabetic CKD, indicating a potential broader applicability beyond diabetes, though evidence remains limited and warrants dedicated trials in non-diabetic populations.
REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD
Q: Do the benefits of semaglutide in Remodel depend on whether patients are also taking an SGLT-2 inhibitor, or are they additive?
The findings suggest that the benefits are largely additive and largely independent of baseline SGLT-2 inhibitor use, implying that GLP-1 receptor agonists add complementary protective mechanisms when used with SGLT-2 inhibitors.
REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD
Q: For listeners who haven't heard about Remodel yet, what was the primary aim of the trial and what were the key findings?
Remodel was designed to answer why semaglutide benefits the kidney, focusing on MRI-based oxygenation outcomes and a suite of mechanistic and clinical secondary outcomes. It found no improvement in intra-renal oxygenation but did show reductions in peri-renal fat, hilar fat, and markers of kidney fibrosis, along with a notable drop in albuminuria; biopsy data suggested favorable effects on endothelial cells and inflammation.
Phase 3 Data on Telitacicept in IgA Nephropathy at ASN Kidney Week 2025
Q: How many patients were randomized and what were the baseline characteristics?
Over 500 screened, about 380 randomized in a one-to-one fashion to teletassiept or placebo, with projections focusing on heavy proteinuria and EGFR risk profiles.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

A practical, expert-focused deep dive into kidney trials, with episodes frequently unpacking trial designs, results, and real-world implications. Listeners are likely clinicians, researchers, and pharma/biotech partners who want clear takeaways on trial data, regulatory context, and evolving standards of care in nephrology. Notable strengths include patient-centered trial interpretations, cross-trial comparisons, and a strong emphasis on translating findings into clinical practice and guideline discussions. The show often features high-profile trial investigators and leaders in IgA nephropathy, CKD therapies, and biomarker-driven approaches, making it a go-to for staying ahead of new treatment paradigms and pragmatic trial design insights.

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

How many episodes of this podcast are there?

this podcast launched a year ago and published 20 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. David Cherney
2. Martin de Borst
3. Hong Zhang
4. Jicheng Liu
5. Sophia Zoungas
6. Danny Gale
7. Brad Rovin
8. Richard Lafayette, MD

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days